Breast Cancer Vaccines

Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against breast cancer and guarantee the finest results for our customers all over the world.

Breast Cancer

Breast cancer is the most common malignancy diagnosed in women worldwide, with an estimated 1.7 million new cases in 2012. It remains a major public health problem even in developed countries, with more than 40,000 deaths in the United States annually. Optimization of standard therapies for breast cancer, including surgery, radiation therapy, endocrine therapy, and chemotherapy, has generated small but steady improvements in overall survival (OS) in the last 40 years. In the last 15 years, targeted therapies that inhibit critical pathways driving breast tumor growth and progression (such as the human epidermal growth factor receptor [HER-2], mammalian target of rapamycin [mTOR], and the cyclin-dependent kinases [CDKs]) have led to further improvements in clinical outcomes. Most recently, activating the immune system to reject breast cancers has emerged as a promising strategy for breast cancer therapy. Monoclonal antibodies that target the programmed death l (PD-1) pathway have demonstrated objective clinical responses in a subset of patients with triple negative breast cancer (TNBC) and luminal (estrogen receptor positive [ER⁺]) disease. This, together with the durable responses obtained with blockade of the PD-1 pathway across multiple solid tumor types, has sparked intense interest in developing effective immunotherapies for all breast cancer patients.

Vaccines for Primary Prevention

The primary prevention of breast cancer in patients at high risk of developing invasive disease would be ideal. This has been evaluated in patients with ductal carcinoma in situ (DCIS), a premalignant precursor to invasive breast cancer that is typically managed with surgery, with the addition of endocrine therapy for DCIS that is ER⁺. A clinical trial evaluated the intranodal injection of DCs loaded with HER-2 peptides in 27 patients with DCIS. This vaccine induced high numbers of HER-2-specific T cells.

Vaccines for Secondary Prevention

The HER-2-derived peptide vaccine E75 (nelipepimut-S) given with GMCSF adjuvant has been extensively studied in the adjuvant setting for the prevention of relapse after a standard breast cancer therapy. A second vaccine tested for secondary breast cancer prevention is the MHC class II epitope vaccine AE37, which is the HER-2 AE36 epitope derived from the HER-2 ICD covalently linked to the Ii-Key peptide LRMK to enhance epitope charging and augment antigen presentation.

Vaccines for Metastatic Disease

Breast cancer vaccines that target carbohydrate antigens and mucin-1 (MUC-1) have been tested extensively in metastatic breast cancer. MUC-1 is an aberrantly glycosylated protein expressed in transformed cells of secretory origin with altered epitopes at carbohydrate residues and peptide sequences unmasked by altered glycosylation. PANVAC is a viral-based vaccine that delivers MUC-1, carcinoembryonic antigen (CEA) and three co-stimulatory molecules (B7.1, ICAM-1, and LFA-3); it has been recently tested in 48 patients with metastatic breast cancer. Early trials of PANVAC demonstrated safety, immune responses, and possible clinical activity.

HER-2 peptide and protein vaccines has been tested by giving the adjuvant granulocyte-macrophage colony stimulating factor (GM-CSF) to metastatic breast cancer patients.

Another type of vaccine, an allogeneic GM-CSF-secreting breast cancer vaccine that delivers multiple antigens, including HER-2, has been evaluated. With this vaccine, the paracrine secretion of GM-CSF results in a large influx of DCs at the vaccine site, where vaccine antigens are processed and presented to CD4⁺ and CD8⁺ T cells to cross-prime the antitumor immune response. This vaccine was tested in sequence with a range of immune-modulating doses of CY and doxorubicin (DOX), with the induction of increased HER-2- specific DTH and antibody responses maximized at the lowest dose of CY and the highest dose of DOX tested.

Our Breast Cancer Vaccine Platforms

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the development of the breast cancer vaccines. If you are interested in our services, please contact us for more details.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.